SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis

British Journal of Dermatology

Volumn 144, Issue 4, 2001, Pages 788-794

  Luger, T ^a   Van Leent, E J M ^b   Graeber, M ^c   Hedgecock, S ^c   Thurston, M ^c   Kandra, A ^c   Berth Jones, J ^d   Bjerke, J ^e   Christophers, E ^f   Knop, J ^g   Knulst, A C ^h   Morren, M ⁱ   Morris, A ^j   Reitamo, S ^k   Roed Petersen, J ^l   Schoepf, E ^m   Thestrup Pedersen, K ⁿ   Van Der Valk, P G M ^o   Bos, J D ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NOVARTIS PHARMA AG   (Switzerland)

^d WALSGRAVE HOSPITAL   (United Kingdom)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF KIEL   (Germany)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ University Hospital   (Denmark)

^j QUEEN S MEDICAL CENTRE   (United Kingdom)

^k UNIVERSITY OF HELSINKI   (Finland)

^l GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ AARHUS UNIVERSITY   (Denmark)

^o Medical Center   (Netherlands)

more..

Author keywords

Ascomycin macrolactam; Atopic dermatitis; Dose finding; SDZ ASM 981 cream

Indexed keywords

PIMECROLIMUS;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 17744379151     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04134.x     Document Type: Article

References (11)

1. The epidemiology of atopic dermatitis
2. Pathogenesis of atopic eczema
3. Perinatal factors influencing the development of allergy
4. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
5. A potential new anti-inflamatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
6. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
7. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions
8. Diagnostic features of atopic dermatitis
9. Grading of the severity of atopic dermatitis
10. Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis
11. SDZ ASM 981 does not induce skin atrophy: A randomised double-blind controlled study